Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2010 Jan;16(1):35-45.
doi: 10.1016/j.bbmt.2009.08.011. Epub 2009 Oct 4.

A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR

Hillard M Lazarus  1 , Mei-Jie Zhang, Jeanette Carreras, Brandon M Hayes-Lattin, Asli Selmin Ataergin, Jacob D Bitran, Brian J Bolwell, César O Freytes, Robert Peter Gale, Steven C Goldstein, Gregory A Hale, David J Inwards, Thomas R Klumpp, David I Marks, Richard T Maziarz, Philip L McCarthy, Santiago Pavlovsky, J Douglas Rizzo, Thomas C Shea, Harry C Schouten, Shimon Slavin, Jane N Winter, Koen van Besien, Julie M Vose, Parameswaran N Hari
Affiliations
Comparative Study

A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR

Hillard M Lazarus et al. Biol Blood Marrow Transplant. 2010 Jan.

Abstract

We compared outcomes of 916 diffuse large B cell lymphoma (DLBCL) patients aged >or=18 years undergoing first autologous (n = 837) or myeloablative (MA) allogeneic hematopoietic cell transplant (HCT) (n = 79) between 1995 and 2003 reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). Median follow-up was 81 months for allogeneic HCT versus 60 months for autologous HCT. Allogeneic HCT recipients were more likely to have high-risk disease features including higher stage, more prior chemotherapy regimens, and resistant disease. Allogeneic HCT was associated with a higher 1 year treatment-related mortality (TRM) (relative risk [RR] 4.88, 95% confidence interval [CI], 3.21-7.40, P < .001), treatment failure (RR 2.06, 95% CI, 1.54-2.75, P < .001), and mortality (RR 2.75, 95% CI, 2.03-3.72, P < .001). Risk of disease progression was similar in the 2 groups (RR 1.12, 95% CI, 0.73-1.72, P = .59). In fact, for 1-year survivors, no significant differences were observed for TRM, progression, progression-free (PFS) or overall survival (OS). Increased risks of TRM and mortality were associated with older age (>50 years), lower performance score, chemoresistance, and earlier year of transplant. In a cohort of mainly high-risk DLBCL patients, upfront MA allogeneic HCT, although associated with increased early mortality, was associated with a similar risk of disease progression compared to lower risk patients receiving autologous HCT.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cumulative incidence of treatment-related mortality after autologous and HLA-identical sibling HCTs for diffuse large B-cell lymphoma
Figure 2
Figure 2
Cumulative incidence of progression/relapse after autologous and HLA-identical sibling HCTs for diffuse large B-cell lymphoma
Figure 3
Figure 3
Probability of progression-free survival after autologous and HLA-identical sibling HCTs for diffuse large B-cell lymphoma
Figure 4
Figure 4
Probability of overall survival after autologous and HLA-identical sibling HCTs for diffuse large B-cell lymphoma
See this image and copyright information in PMC

References

    1. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242. - PubMed
    1. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23:4117–4126. - PubMed
    1. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379–391. - PubMed
    1. Blay J, Gomez F, Sebban C, et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood. 1998;92:3562–3568. - PubMed
    1. Nademanee A, Molina A, Dagis A, et al. Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma. Clin Lymphoma. 2000;1:46–54. - PubMed

Publication types

MeSH terms